Psychometric performance of the CFQ-R-8D compared to the EQ-5D-3L and SF-6D in people with cystic fibrosis.
Cost utility
Cystic Fibrosis Questionnaire-Revised
Cystic Fibrosis Questionnaire–Revised–8 Dimensions
Cystic fibros
EQ-5D-3L
Patient-reported outcomes
Quality of life
Short Form 6 Dimensions
Short Form 6 Dimensions; SF-6D
Journal
Journal of patient-reported outcomes
ISSN: 2509-8020
Titre abrégé: J Patient Rep Outcomes
Pays: Germany
ID NLM: 101722688
Informations de publication
Date de publication:
28 Feb 2024
28 Feb 2024
Historique:
received:
15
06
2023
accepted:
04
02
2024
medline:
28
2
2024
pubmed:
28
2
2024
entrez:
28
2
2024
Statut:
epublish
Résumé
This study aimed to compare the psychometric performance of the Cystic Fibrosis Questionnaire-Revised-8 Dimensions (CFQ-R-8D), a new, condition-specific, preference-based measure, with that of generic preference-based measures EQ-5D-3L and Short Form 6 dimensions (SF-6D). Data from three trials of participants with CF aged ≥ 14 years who completed the CFQ-R and EQ-5D-3L or SF-6D were used. Analyses were undertaken to evaluate convergent validity based on correlations with CFQ-R domain scores. Known-group validity was assessed based on percent predicted forced expiratory volume in one second and pulmonary exacerbations. Responsiveness was based on correlation of change and sensitivity to change based on change in symptom severity. Effect sizes and standardized response means were estimated. CFQ-R-8D utilities and dimensions were strongly correlated with most of the overlapping CFQ-R domain scores (ρ > 0.5); EQ-5D-3L and SF-6D utilities and dimensions had moderate (ρ > 0.3) to strong correlations in dimensions capturing similar concepts. All measures showed evidence of known-group validity (P < 0.05). Change correlations were strong for CFQ-R-8D utilities and dimensions and CFQ-R, but they were moderate for SF-6D and mostly weak ((ρ > 0.1) for EQ-5D-3L. The SF-6D had the largest mean change over time and effect sizes, followed by CFQ-R-8D and then EQ-5D-3L. Neither CFQ-R-8D or SF-6D utility scores had ceiling effects (< 9% responses in full health) compared with those of EQ-5D-3L (61-62%). In participants classified as being in full health by EQ-5D-3L, CFQ-R-8D captured CF-specific health problems, particularly cough, abdominal pain, and breathing difficulty. The CFQ-R-8D reflected known-group differences and changes over time with stronger evidence of good psychometric performance than EQ-5D-3L and similar evidence as SF-6D. Additionally, the CFQ-R-8D captured more condition-specific symptoms than EQ-5D-3L or SF-6D, which are important determinants of health-related quality of life for people with CF.
Identifiants
pubmed: 38416239
doi: 10.1186/s41687-024-00697-w
pii: 10.1186/s41687-024-00697-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
24Subventions
Organisme : Vertex Pharmaceuticals Incorporated
ID : Vertex Pharmaceuticals Incorporated
Informations de copyright
© 2024. The Author(s).
Références
Prieto L, Sacristan JA (2003) Problems and solutions in calculating quality-adjusted life years (QALYs). Health Qual Life Outcomes 1:80
doi: 10.1186/1477-7525-1-80
pubmed: 14687421
pmcid: 317370
Dolan P (1997) Modeling valuations for EuroQol health states. Med Care 35:1095–1108
doi: 10.1097/00005650-199711000-00002
pubmed: 9366889
EuroQol Research Foundation (2018) EQ-5D-3L user guide. EuroQol Research Foundation, Rotterdam, the Netherlands
National Institute for Health and Care Excellence (2013) Guide to the methods of technology appraisal 2013
Finch AP, Brazier JE, Mukuria C (2018) What is the evidence for the performance of generic preference-based measures? A systematic overview of reviews. Eur J Health Econ 19:557–570
doi: 10.1007/s10198-017-0902-x
pubmed: 28560520
Elborn JS (2016) Cystic fibrosis. Lancet 388:2519–2531
doi: 10.1016/S0140-6736(16)00576-6
pubmed: 27140670
Solem CT, Vera-Llonch M, Liu S, Botteman M, Castiglione B (2016) Impact of pulmonary exacerbations and lung function on generic health-related quality of life in patients with cystic fibrosis. Health Qual Life Outcomes 14:63
doi: 10.1186/s12955-016-0465-z
pubmed: 27097977
pmcid: 4839094
Acaster S, Mukuria C, Rowen D, Brazier JE, Wainwright CE, Quon BS et al (2023) Development of the cystic fibrosis questionnaire-Revised-8 dimensions: estimating utilities from the cystic fibrosis questionnaire-revised. Value Health 6:567–578
The Pharmaceutical Benefits Advisory Committee (2016) Guidelines for preparing a submission to the Pharmaceutical Benefits Advisory Committee version 5.0. The Pharmaceutical Benefits Advisory Committee
Kennedy-Martin M, Slaap B, Herdman M, van Reenen M, Kennedy-Martin T, Greiner W et al (2020) Which multi-attribute utility instruments are recommended for use in cost-utility analysis? A review of national health technology assessment (HTA) guidelines. Eur J Health Econ 21:1245–1257
doi: 10.1007/s10198-020-01195-8
pubmed: 32514643
pmcid: 7561556
Quittner AL, Buu A, Messer MA, Modi AC, Watrous M (2005) Development and validation of the cystic fibrosis questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis. Chest 128:2347–2354
doi: 10.1378/chest.128.4.2347
pubmed: 16236893
Quittner AL, Sawicki GS, McMullen A, Rasouliyan L, Pasta DJ, Yegin A et al (2012) Erratum to: psychometric evaluation of the Cystic Fibrosis Questionnaire- Revised in a national, US sample. Qual Life Res 21:1279–1290
doi: 10.1007/s11136-011-0091-5
pubmed: 22240933
Brazier JE, Roberts J (2004) The estimation of a preference-based measure of health from the SF-12. Med Care 42:851–859
doi: 10.1097/01.mlr.0000135827.18610.0d
pubmed: 15319610
Goss CH, Edwards TC, Ramsey BW, Aitken ML, Patrick DL (2009) Patient-reported respiratory symptoms in cystic fibrosis. J Cyst Fibros 8:245–252
doi: 10.1016/j.jcf.2009.04.003
pubmed: 19481983
Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M et al (2015) Lumacaftor- ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med 373:220–231
doi: 10.1056/NEJMoa1409547
pubmed: 25981758
pmcid: 4764353
Taylor-Cousar JL, Munck A, McKone EF, van der Ent CK, Moeller A, Simard C et al (2017) Tezacaftor-Ivacaftor in patients with cystic fibrosis homozygous for Phe508del. N Engl J Med 377:2013–2023
doi: 10.1056/NEJMoa1709846
pubmed: 29099344
Cohen J (1992) A power primer. Psychol Bull 112:155–159
doi: 10.1037/0033-2909.112.1.155
pubmed: 19565683
Mokkink LB, Terwee CB, Patrick DL, Alonso J, Stratford PW, Knol DL et al (2010) The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported outcomes. J Clin Epidemiol 63:737–745
doi: 10.1016/j.jclinepi.2010.02.006
pubmed: 20494804
De Vet HCW, Terwee CB, Mokkink LB, Knol DL (2011) Measurement in Medicine: a practical guide. Cambridge University Press, pp 1–338
Fayers P, Machin D (2007) Quality of life: the assessment, analysis and interpretation of patient-reported outcomes, 2nd edn. Wiley, Chichester, UK
doi: 10.1002/9780470024522
Janssen MF, Szende A, Cabases J, Ramos-Goñi JM, Vilagut G, König HH (2019) Population norms for the EQ-5D-3L: a cross-country analysis of population surveys for 20 countries. Eur J Health Econ 20:205–216
doi: 10.1007/s10198-018-0955-5
pubmed: 29445941
Rowen D, Brazier J, Ara R, Azzabi Zouraq I (2017) The role of condition-specific preference-based measures in health technology assessment. PharmacoEconomics 35:33–41
doi: 10.1007/s40273-017-0546-9
pubmed: 29052164